Literature DB >> 7875671

Endothelin-1 and -3 plasma concentrations in patients with cirrhosis: role of splanchnic and renal passage and liver function.

A L Gerbes1, S Møller, V Gülberg, J H Henriksen.   

Abstract

Increased as well as decreased plasma concentrations of the endothelins, endogenous vasoactive peptides, have been reported in cirrhosis. This might be caused by alterations of hepatic or renal clearance or release. Therefore, the aim of the current study was to investigate the influence of splanchnic and renal passage and of liver function on plasma concentrations of endothelin-1 (ET-1) and endothelin-3 (ET-3) in patients with cirrhosis compared with controls. Eighteen patients with cirrhosis and 8 normotensive controls of similar age were investigated. Arterial and venous plasma samples were obtained simultaneously, and ET-1 and ET-3 concentrations were determined in extracted plasma by two separate radioimmunoassays. Arterial as well as hepatic and renal venous concentrations of ET-1 in cirrhosis (17.8 +/- 0.8 pg/mL, 19.1 +/- 0.9 pg/mL, and 16.8 +/- 0.8 pg/mL) were significantly (P < .001) higher than in controls (9.2 +/- 1.7 pg/mL, 9.0 +/- 2.0 pg/mL, and 8.4 +/- 1.9 pg/mL, respectively). The same held true for the corresponding ET-3 plasma concentrations in cirrhosis (19.3 +/- 1.6 pg/mL, 20.5 +/- 1.5 pg/mL, and 18.4 +/- 1.5 pg/mL, respectively) compared with controls (11.1 +/- 1.8 pg/mL, 11.3 +/- 1.5 pg/mL, and 10.1 +/- 1.7 pg/mL, respectively; P < .01). There was a significant (P < .05) renal net extraction of ET-1 and ET-3 in cirrhosis. In contrast, a significant (P < .05) net release of ET-1 and ET-3 (2.40 +/- 0.80 ng/min and 1.75 +/- 1.16 ng/min) during splanchnic passage was observed in cirrhosis, but not in controls (-0.24 +/- 0.51 ng/min, and -0.46 +/- 0.64 ng/min).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7875671

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  19 in total

Review 1.  Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension.

Authors:  H Reynaert; M G Thompson; T Thomas; A Geerts
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

2.  Elevated levels of endothelin-1 in hepatic venous blood are associated with intrapulmonary vasodilatation in humans.

Authors:  David G Koch; Galina Bogatkevich; Venkat Ramshesh; John J Lemasters; Renan Uflacker; Adrian Reuben
Journal:  Dig Dis Sci       Date:  2011-10-01       Impact factor: 3.199

3.  Portopulmonary hypertension in cirrhosis: the pathogenetic challenge.

Authors:  F Wong
Journal:  Gut       Date:  2005-02       Impact factor: 23.059

Review 4.  Role of endothelin in systemic and portal resistance in cirrhosis.

Authors:  P W Angus
Journal:  Gut       Date:  2006-09       Impact factor: 23.059

Review 5.  Portopulmonary hypertension.

Authors:  Michael Halank; Ralf Ewert; Hans-Juergen Seyfarth; Gert Hoeffken
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

6.  Hyperendothelinemia and ICG clearance in alcoholic and nonalcoholic cirrhosis.

Authors:  Shigeo Maruyama; Chisato Hirayama; Satoru Yamamoto; Masaharu Koda; Akihiro Udagawa; Yoshiro Kadowaki; Masayuki Inoue; Atsushi Sagayama; Kensuke Umeki
Journal:  Dig Dis Sci       Date:  2002-04       Impact factor: 3.199

7.  Sodium handling in patients with well compensated cirrhosis is dependent on the severity of liver disease and portal pressure.

Authors:  R Jalan; P C Hayes
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

8.  Evidence for altered vascular responses to exogenous endothelin-1 in patients with advanced cirrhosis with restoration of the normal vasoconstrictor response following successful liver transplantation.

Authors:  R B Vaughan; P W Angus; J P F Chin-Dusting
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

9.  Portopulmonary hypertension in decompensated cirrhosis with refractory ascites.

Authors:  F S Benjaminov; M Prentice; K W Sniderman; S Siu; P Liu; F Wong
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

10.  Endothelin and vascular function in liver disease.

Authors:  K Moore
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.